



# **Prevalence and Risk Factors for Hydroxychloroquine Retinopathy among Patients with Systemic Lupus Erythematosus**

**Thesis**

*Submitted for Partial Fulfilment of  
Master Degree in **Internal Medicine***

**By**

***Fatma Ibrahim Mabrouk Ahmed***  
*M.B.B.Ch, M.SC*

**Under Supervision of**

**Prof. Dr./Mohamed Salah El-din Abdel Baky**  
*Professor of Internal Medicine & Rheumatology  
Faculty of Medicine, Ain Shams University*

**Prof. Dr./ Tarek Ahmed El-Mamoun**  
*Professor of Ophthalmology  
Faculty of Medicine, Ain Shams University*

**Dr./Rasha Mohamed Hassan**  
*Lecturer of Internal Medicine & Rheumatology  
Faculty of Medicine, Ain Shams University*

**Faculty of Medicine, Ain Shams University**  
**2019**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

# قَالَ

سَبِّحَانَكَ لَا إِلَهَ إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ  
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

# Acknowledgments

*First and foremost, I feel always indebted to **Allah** the Most Beneficent and Merciful.*

*I wish to express my deepest thanks, gratitude and appreciation to **Prof. Dr./Mohamed Salah El-din Abdel Baky**, Professor of Internal Medicine & Rheumatology, Faculty of Medicine, Ain Shams University, for his meticulous supervision, kind guidance, valuable instructions and generous help.*

*Special thanks are due to **Prof. Dr./ Tarek Ahmed El-Mamoun**, Professor of Ophthalmology, Faculty of Medicine, Ain Shams University, for his sincere efforts, fruitful encouragement.*

*I am deeply thankful to **Dr./Rasha Mohamed Hassan**, Lecturer of Internal Medicine & Rheumatology, Faculty of Medicine, Ain Shams University, for her great help, outstanding support, active participation and guidance.*

*I would like to express my hearty thanks to all my family for their support till this work was completed.*

**Fatma Ibrahim Mabrouk Ahmed**

# List of Contents

Title	Page No.
List of Tables.....	5
List of Figures .....	8
List of Abbreviations.....	10
Introduction .....	- 1 -
Aim of the Work .....	17
Review of Literature	
▪ Systemic Lupus Erythematosus .....	18
▪ Hydroxychloroquine .....	48
▪ Hydroxychloroquine-Induced Retinal Toxicity .....	72
Subjects and Methods.....	92
Results.....	96
Discussion .....	124
Summary.....	132
Conclusion .....	135
Recommendations .....	136
References .....	137
Arabic Summary	

# List of Tables

Table No.	Title	Page No.
<b>Table (1):</b>	ISN/RPS 2003 classification of lupus nephritis. ....	24
<b>Table (2):</b>	Neuropsychiatric syndromes seen in systemic lupus erythematosus.....	29
<b>Table (3):</b>	ACR/SLICC revised criteria for diagnosis of SLE .....	33
<b>Table (4):</b>	Investigations of SLE and monitoring after diagnosis .....	35
<b>Table (5):</b>	Further investigations in SLE.....	36
<b>Table (6):</b>	Mechanism of anti-inflammatory action of Hydroxychloroquine. ....	52
<b>Table (7):</b>	Details the differences in screening recommendations and risk factors for HCQ/CQ retinopathy. ....	79
<b>Table (8):</b>	Comparison of screening guidelines for HCQ/CQ retinopathy .....	83
<b>Table (9):</b>	Sensitivity and specificity of diagnostic tests in HCQ retinopathy. ....	89
<b>Table (10):</b>	Demographic data among the studied patients.....	96
<b>Table (11):</b>	Body weight and dose/kg among the studied patients.....	97
<b>Table (12):</b>	Clinical manifestations of SLE among the studied patients.....	98
<b>Table (13):</b>	SLEDAI score of the studied patients .....	99
<b>Table (14):</b>	Laboratory data among the studied patients .....	100
<b>Table (15):</b>	Immunological markers of the studied patients.....	102
<b>Table (16):</b>	Fundus examination results among the studied patients.....	104

# List of Tables *cont...*

Table No.	Title	Page No.
<b>Table (17):</b>	Fundus auto fluorescence (FAF) results among the studied patients .....	105
<b>Table (18):</b>	Hydroxychloroquine dose and duration among the studied patients .....	106
<b>Table (19):</b>	Best Corrected Visual Acuity among our studied patients (BCVA) .....	107
<b>Table (20):</b>	Comparison between normal FAF group and abnormal FAF group regarding age and sex of the studied patients .....	108
<b>Table (21):</b>	Comparison between normal FAF group and abnormal FAF group regarding body weight and dose/kg among studied patients .....	110
<b>Table (22):</b>	Comparison between normal FAF group and abnormal FAF group regarding Clinical manifestations of SLE among the studied patients .....	111
<b>Table (23):</b>	Comparison between normal FAF group and abnormal FAF group regarding SLEDAI score of the studied patients .....	112
<b>Table (24):</b>	Comparison between SLEDAI score for SLE activity , body weight and dose/kg.....	113
<b>Table (25):</b>	Comparison between normal FAF group and abnormal FAF group regarding laboratory data of the studied patients .....	114
<b>Table (26):</b>	Comparison between normal FAF group and abnormal FAF group regarding immunological markers of the studied patients .....	117
<b>Table (27):</b>	Comparison between normal FAF group and abnormal FAF group regarding fundus abnormality. ....	119

# List of Tables *cont...*

Table No.	Title	Page No.
<b>Table (28):</b>	Comparison between normal FAF group and abnormal FAF group regarding dose & duration of hydroxychloroquine therapy. ....	120
<b>Table (29):</b>	Comparison between normal FAF group and abnormal FAF group regarding Best Corrected Visual Acuity of both eyes. ....	122

# List of Figures

Fig. No.	Title	Page No.
<b>Figure (1):</b>	Shows: SLICC classification criteria for Systemic Lupus Erythematosus .....	32
<b>Figure (2):</b>	Chemical structure of Hydroxychloroquine.....	49
<b>Figure (3):</b>	Role of antimalarial agents in TLR-mediated innate immune pathways in SLE.....	54
<b>Figure (4):</b>	The classical visual cycle involves the cycling of retinoids between the rod outer segments (OS) and the RPE.....	75
<b>Figure (5):</b>	Bull's eye maculopathy.....	81
<b>Figure (6):</b>	Gender distribution among the studied patients. ....	96
<b>Figure (7):</b>	Urinary albumin among the studied patients. ....	101
<b>Figure (8):</b>	Urinary casts among the studied patients. ....	101
<b>Figure (9):</b>	ANA and DNA among the studied patients. ....	103
<b>Figure (10):</b>	C3 and C4 levels among the studied patients. ....	103
<b>Figure (11):</b>	Fundus examination among the studied patients. ....	104
<b>Figure (12):</b>	FAF results of the studied patients. ....	105
<b>Figure (13):</b>	FAF results of the studied patients. ....	106
<b>Figure (14):</b>	Comparison between normal FAF group and abnormal FAF group regarding age. ....	109
<b>Figure (15):</b>	Comparison between normal FAF group and abnormal FAF group regarding sex.....	109
<b>Figure (16):</b>	Comparison between normal FAF group and abnormal FAF group regarding TLC and Hb levels .....	115
<b>Figure (17):</b>	Comparison between normal FAF group and abnormal FAF group regarding platelet level.....	115



# List of Figures *cont...*

Fig. No.	Title	Page No.
<b>Figure (18):</b>	Comparison between normal FAF group and abnormal FAF group regarding ESR level .....	116
<b>Figure (19):</b>	Comparison between normal FAF group and abnormal FAF group regarding CRP level .....	116
<b>Figure (20):</b>	Comparison between normal FAF group and abnormal FAF group regarding ANA and DNA levels. ....	118
<b>Figure (21):</b>	Comparison between normal FAF group and abnormal FAF group regarding C3 level. ....	118
<b>Figure (22):</b>	Comparison between normal FAF group and abnormal FAF group regarding fundus abnormality. ....	119
<b>Figure (23):</b>	Comparison between normal FAF group and abnormal FAF group regarding duration of hydroxychloroquine therapy. ....	121
<b>Figure (24):</b>	Comparison between normal FAF group and abnormal FAF group regarding best corrected visual acuity of both eyes. ....	122
<b>Figure (25):</b>	Receiver operating characteristic curve (ROC) for predictors of abnormal FAF cases. ....	123

# List of Abbreviations

Abb.	Full term
AAO .....	<i>American Academy of Ophthalmology</i>
ABCR.....	<i>Atp binding cassette transporter</i>
ABW .....	<i>Actual body weight</i>
ACLE .....	<i>Acute cutaneous lupus erythematosus</i>
ACR .....	<i>American College of Rheumatology</i>
AF .....	<i>Autoflourescence</i>
ALMS .....	<i>Aspreva Lupus Management Study</i>
ANA .....	<i>Antinuclear antibody</i>
ANCA.....	<i>Anti Neutrophil Cytoplasmic Antibody</i>
Anti-DNA.....	<i>Anti Deoxyribonucleic acid</i>
Anti-Sm .....	<i>Anti-Smith antibody</i>
APC.....	<i>Antigen Presenting Cell</i>
aPL .....	<i>Anti-phospholipid antibody</i>
APS.....	<i>Antiphospholipid Syndrome</i>
AZA.....	<i>Azathioprine</i>
BAFF .....	<i>B-cell activating factor</i>
BDCQ .....	<i>Bisdesethylchloroquine.</i>
BILAG .....	<i>British Isles Lupus Assessment Group</i>
Blys.....	<i>B-lymphocyte stimulator</i>
BUN.....	<i>Blood urea nitrogen</i>
C3.....	<i>Complement 3</i>
C4.....	<i>Complement 4</i>
CBC .....	<i>Complete blood picture</i>
CCLE .....	<i>Chronic cutaneous lupus eryhtematosus</i>
CD.....	<i>Cluster of differentiation</i>
CNS .....	<i>Central nervous system</i>
CpG.....	<i>Cytosine phosphate diester guanine</i>
CPK.....	<i>Creatine phospho-kinase</i>
CQ .....	<i>Coloroquine</i>
CRALBP .....	<i>Cellular retinaldyhyde binding protein</i>
CRBP.....	<i>Cellular retinoid binding binding protein</i>
CRP.....	<i>C-reactive protein</i>
CSA.....	<i>Cyclosporin</i>
CTLA-4.....	<i>Cytotoxic T-lymphocyte-associated protein 4</i>

# List of Abbreviations cont...

Abb.	Full term
CYC.....	Cyclophosphamide
DCQ.....	Desethylchloroquine
DLE .....	Discoid lupus erythematosus
DMARD.....	Disease-modifying antirheumatic drugs
ECLAM.....	European Consensus Lupus Activity Measurement
ELISA.....	Enzyme-linked immunosorbent assay
ESR.....	Erythrocyte sedimentation rate
FAF .....	Fundus autofluorescence
FAF.....	Fundus autofluorescence imaging
FDA .....	Food and Drug Administration
G6PD .....	Glucose-6-phosphate dehydrogenase deficiency
GLADEL.....	Grupo Latino Americano de Estudio de Lupus Eritematoso
HCQ .....	Hydroxychloroquine
HEK293 .....	Human embryonic kidney cells
Hgb .....	Hemoglobin
HLA .....	Human leucocyte antigen
Hpf.....	High power field
HPLC.....	High-performance liquid chromatography
HR.....	Hazard Ratio
IBW .....	Ideal body weight
IFN- $\gamma$ .....	Interferon gamma
IgG.....	Immunoglobulin G
IL .....	Interleukin
IRBP.....	Interphotoreceptor retinoid binding protein
ISN .....	International Society of Nephrology
ISN/RPS.....	International Society of Nephrology / Renal Pathology Society
LN.....	Lupus nephritis
LRAT.....	Lecithin retinol acyl transferase

# List of Abbreviations cont...

Abb.	Full term
LUMINA.....	<i>Lupus in Minorities; nature versus nurture</i>
mfERG .....	<i>Multifocal electroretinography</i>
MHC .....	<i>Major histocompatibility complex</i>
MMF.....	<i>Mycophenolate Mofetil</i>
MPA.....	<i>Mycophenolic acid</i>
MRA.....	<i>Magnetic resonance angiography</i>
MRI.....	<i>Magnetic resonance imaging</i>
MTX.....	<i>Methotrexate</i>
NETs.....	<i>Neutrophil extracellular traps sequester circulating tumor cells</i>
NIH.....	<i>National Institute of Health</i>
NPSLE .....	<i>Neuropsychiatric systemic lupus erythematosus</i>
NSAID.....	<i>Non-steroidal anti-inflammatory drugs</i>
OATP1A2 .....	<i>Organic anion transporting polypeptide 1A2</i>
OCT .....	<i>Optical coherence tomography</i>
OS .....	<i>Rod outer segment</i>
P.Ovale .....	<i>Plasmodium Ovale</i>
pDCs.....	<i>Plasmacytoid dendritic cells</i>
PIP.....	<i>Proximal inter-phalangeal</i>
PLT.....	<i>Platelets</i>
PMNs.....	<i>Polymorphonuclear cells</i>
RA.....	<i>Rheumatoid Arthritis</i>
RBC .....	<i>Red blood cell</i>
RCOphth .....	<i>Royal college of ophthalmologist</i>
RNA.....	<i>Ribonucleic acid</i>
RNP.....	<i>Ribonucleoprotein</i>
RPE .....	<i>Retinal pigmented epithelium</i>
SCLE .....	<i>Subacute cutaneous lupus erythematosus</i>
SD-OCT .....	<i>Spectral domain optical coherence tomography</i>

# List of Abbreviations cont...

Abb.	Full term
<i>SELENA</i> .....	<i>Safety of Estrogens in Lupus Erythematosus - National Assessment</i>
<i>SLAM</i> .....	<i>Systemic Lupus Activity Measure</i>
<i>SLE</i> .....	<i>Systemic Lupus Erythematosus</i>
<i>SLEDAI</i> .....	<i>Systemic Lupus Erythematosus Disease Activity Index</i>
<i>SLICC</i> .....	<i>Systemic Lupus International Collaborating Clinics</i>
<i>TB</i> .....	<i>Tuberculosis</i>
<i>TH</i> .....	<i>T-helper</i>
<i>TLR</i> .....	<i>Toll like receptor</i>
<i>TNF</i> .....	<i>Tumor necrosis factor</i>
<i>TREG</i> .....	<i>T-regulatory cell</i>
<i>UVR</i> .....	<i>Ultraviolet rays</i>
<i>VF</i> .....	<i>Visual field</i>
<i>WBC</i> .....	<i>White blood cell</i>
<i>WHO</i> .....	<i>World health organization</i>

# INTRODUCTION

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with unclear etiology that affects multiple organs and affects mostly women of childbearing age. The skin, blood vessels, kidneys, central nervous system and joints are common targets of inflammation at onset or during the course of the disease. The development of SLE is attributed to disruptions in adaptive immunity, triggered by genetic predisposing factors and environmental triggers, which lead to the loss of tolerance to self-antigens (*Qin et al., 2016*).

SLE has a relapsing-remitting course, with patients experiencing disease activity flares over time. Aiming at flare reduction, Hydroxychloroquine is the standard treatment for most SLE patients during the entire disease course and conventional immunosuppressors are given to those with severe organ involvement (*Inês et al., 2014*).

Hydroxychloroquine (HCQ) is an antimalarial medication that has been used for many years to reduce inflammation in the treatment of patients with multiple rheumatologic diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) (*Stelton et al., 2013*).

Antimalarial medications (HCQ and chloroquine) are among the safest ant rheumatic medications as they are rarely associated with side effects. The most common adverse effects

are related to the gastrointestinal tract, skin, and nervous system (*Felson et al., 1990*).

However, one of the most serious side effects is ocular toxicity, which has been found to be more common when HCQ is used for long periods of time (*Flach, 2007*).

Therefore, there is considerable concern about the risk of ocular problems among patients treated with HCQ, and regular screening (in accordance with standard guidelines) is necessary, even in the absence of ocular symptoms. HCQ-induced ocular toxicity can occur in two distinct areas of the eye: the cornea and the macula (*Marmor et al., 2011*).

The changes in the macula can potentially be serious, as the consequences can include loss of vision. The mechanism by which antimalarial medications cause retinal toxicity involves the binding of the drugs to the melanin in the pigmented epithelial layer of the retina, and subsequent damage to rods and cones. Retinal toxicity had been classically characterized as involving bilateral “bull’s-eye” maculopathy, initial photoreceptor damage with a parafoveal distribution, and further damage with a more peripheral extramacular distribution (*Wallace, 2010*).

The risk of developing retinal toxicity has been found to be dependent on the daily HCQ dose and the duration of use. The risk of retinal toxicity is <1% for those who use HCQ for up to 5 years and <2% for those who use HCQ for 5–10 years,